Skip to main content

Table 4 Cross-classification of early pregnancy estradiol and progesterone and breast cancer risk: Northern Sweden Maternity Cohort

From: Early pregnancy sex steroids during primiparous pregnancies and maternal breast cancer: a nested case–control study in the Northern Sweden Maternity Cohort

  Estradiol/progesterone
Low/low (<median/<median) Low/high (<median/≥median) High/low (≥median/<median) High/high (≥median/≥median)
All women Cases/controls 66/141 32/59 47/56 75/145
OR (95% CI) Reference 1.14 (0.67–1.94) 1.87 (1.11–3.16) 1.10 (0.95–1.76)
ER+/PR+ Cases/controls 47/99 22/48 33/37 50/101
OR (95% CI) Reference 0.92 (0.49–1.75) 1.81 (0.97–3.40) 0.98 (0.56–1.71)
ER–/PR– Cases/controls 15/33 6/7 12/16 17/33
OR (95% CI) Reference 1.63 (0.46–5.79) 1.42 (0.43–4.64) 0.80 (0.29–2.15)
  1. Conditional logistic regression controlling for gestational age at blood collection (continuous). Cases with reported ER+/PR– and ER–/PR+ tumors included in analysis of “all women”
  2. CI confidence interval, ER estrogen receptor, OR odds ratio, PR progesterone receptor